 Freeline Therapeutics Holdings plc NASDAQ: FRLN gave an update on its investigational Fabry disease treatment FLT190, currently in a Phase 12 trial, saying the candidate proved durable in the second patient tested. Fabry disease is an inherited metabolic disorder resulting from the absent or markedly deficient activity of lysosomal enzyme α-galactosidase A, or α-Gal A. 